北美莱伯先天性黑蒙市场，按疾病类型（婴儿型、青少年型和其他）、类型（治疗和诊断）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健和其他）、分销渠道（直接招标和零售销售）行业趋势和预测到 2029 年。
市场分析和见解
北美莱伯先天性黑蒙市场受到多种因素的推动，例如糖尿病和胃肠道疾病等慢性病的患病率增加、新兴参与者的数量不断增加以及输液泵家庭护理服务的普及，这些因素增加了市场需求，此外，研发投资的增加也推动了市场增长。目前，正在进行各种研究，预计这将为制造商创造竞争优势，以开发新的创新型莱伯先天性黑蒙治疗和疗法，预计这将为莱伯先天性黑蒙市场提供各种其他机会。然而，政府对输液治疗期间的审批和设备错误的严格规定预计将阻碍增长。
北美莱伯莱伯先天性黑蒙市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入来源、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标，由于保证付款和产品国际销量高，客户偏好度不断提高是推动预测期内市场需求的主要驱动因素。
北美莱伯先天性黑蒙市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，北美莱伯先天性黑蒙市场将以 4.4% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（百万美元），定价（美元） |
|
涵盖的领域 |
按疾病类型（婴儿型、青少年型及其他）、类型（治疗、诊断）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健及其他）、分销渠道（直接招标和零售） |
|
覆盖国家 |
按国家/地区（美国、加拿大、墨西哥） |
|
涵盖的市场参与者 |
Invitae Corporation、Johnson & Johnson Services, Inc.、Spark Therapeutics, Inc.、LKC TECHNOLOGIES, INC.、Amarantus Bioscience Holdings, Inc.、Sucampo Pharmaceuticals, Inc. 和 Orphagen Pharmaceuticals, Inc. 等 |
北美莱伯先天性黑蒙症市场动态
驱动程序
- 增加产品线和临床试验
遗传性视网膜疾病和莱伯先天性黑蒙症治疗的持续创新有可能对市场产生积极影响，因为当这些产品在北美市场获得批准时，市场规模将会增加。由于 LCA 没有药物治疗，主要的市场参与者正在不断创新治疗方法或投资于治疗方法的研发。世界各地正在招募各种正在进行的临床试验，以寻找疾病的治疗机制。
- 提高主要参与者的战略主动性
合作、协议和签署销售协议等战略举措有望推动市场发展，以发明和创新药物治疗。协会，主要参与者利用该协议将市场扩展到世界不同地区，同时将技术从一个参与者传递给其他参与者，从而增加产品批准和机构研究。
增加合作伙伴协议和协作以增加眼部疾病市场中公司的存在将成为市场发展的驱动力。市场参与者已经采取了各种战略举措，这些举措将推动莱伯先天性黑蒙市场的增长。
- rpe65基因介导的视网膜疾病发病率和患病率增加
遗传性视网膜营养不良 (IRD) 是一组遗传多样性的渐进性视力丧失疾病。由于 65 kDa 视网膜色素上皮 (RPE65) 基因的双等位基因突变导致 IRD 而导致视力丧失的成人和儿童患者通常在临床上被诊断为视网膜色素变性 (RP) 和莱伯先天性黑蒙 (LCA)。
莱伯先天性黑蒙 (LCA) 是一种主要影响视网膜的眼部疾病。LCA 的特征是出生或出生后头几个月出现严重的视力障碍、眼球四处乱转或眼球震颤、瞳孔对光反应差、眼球指征（戳、揉和/或按压眼睛）以及全视野视网膜电图 (ERG) 无法检测或严重异常。LCA 通常是一种常染色体隐性遗传病。
机会
- 政府加大力度应对莱伯氏先天性黑蒙症
据世界卫生组织统计，北美地区单基因IRD的患病率约为每4万名新生儿中就有1人患病。为了预防此类疾病，全球多个国家的政府都采取了行动。
世界各国政府为给本国人口提供最佳治疗而采取的各种计划和决定是预计会增加需求的主要因素，并将为北美莱伯先天性黑蒙市场带来机遇。
限制/挑战
- 与手术和治疗相关的高成本
产品成本是市场的主要因素。在遗传性视网膜疾病市场中，普遍观察到产品成本非常复杂，需要精确，其他规格也会增加产品成本。治疗费用高昂是由于治疗过程中检查点众多，以及使用高科技方式进行此类治疗程序。
产品成本是市场的主要因素。在遗传性视网膜疾病市场中，通常观察到产品成本非常复杂，需要精确，其他规格也会增加产品成本。此外，长期治疗相关的费用对于中等收入人群来说相当难以负担。重症监护和重症监护病房服务的使用率在世界范围内不断增加，其昂贵的成本是当前医疗保健系统的主要问题。
患有遗传性疾病的患者通常需要长期治疗，频繁使用药物和其他费用，从而消耗大量医疗资源。因此，大多数无法承担长期经济费用的患者在治疗初期就出院了。但这增加了诊断中出现新并发症的可能性和易感性，需要额外的医疗资源和治疗。
治疗费用高昂是由于治疗的检查点多个以及使用高科技方式进行此类治疗程序。
医院护理进一步增加了莱伯先天性黑蒙症的费用。由于创新和先进产品的成本很高，治疗费用也相应增加，因此莱伯先天性黑蒙症治疗和诊断的高成本预计将抑制莱伯先天性黑蒙症市场的增长。
最新动态
- 2021年4月，Invitae Corporation在北卡罗来纳州开设了新的实验室和生产设施，以进一步扩大其产能，以满足日益增长的基因检测服务需求。
- 2017 年 7 月，Spark Therapeutics, Inc 向欧洲药品管理局 (EMA) 提交了 LUXTURNA（voretigene neparvovec 的拟议商品名）的营销授权申请 (MAA)。此举增加了公司的收入和产品组合。
北美莱伯先天性黑蒙症市场差距
北美莱伯先天性黑蒙市场分为疾病类型、类型、最终用户和分销渠道。各细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。
疾病类型
- 婴儿型
- 幼年型
- 其他的
根据疾病类型，莱伯先天性黑蒙症市场分为婴儿型、青少年型和其他型
类型
- 诊断
- 治疗
根据类型，莱伯先天性黑蒙市场细分为诊断和治疗。诊断部分进一步细分为临床诊断和基因诊断。临床诊断进一步细分为临床眼科检查、视野测试、零售成像和电生理测试。临床诊断细分为电生理测试、视网膜成像、视野测试和临床眼科检查。电生理测试细分为全视野视网膜电图 (ERG) 和暗适应测量 (DA)。视网膜成像细分为光学相干断层扫描 (OCT)、眼底自发荧光成像 (FAF)、扫描激光检眼镜 (SLO) 和自适应光学 (AO) 成像和传统彩色眼底成像。视野测试细分为计算机化视野测试和手动视野测试。临床检查细分为裂隙灯、间接检眼镜、屈光测试和散瞳检查。治疗领域进一步细分为基因治疗、视网膜治疗、神经保护剂和其他。基因治疗进一步细分为 luxturna 和其他。神经保护剂进一步细分为维生素 A 棕榈酸酯、二十二碳六烯酸 (DHA)、叶黄素和其他。
最终用户
- 医院
- 专科诊所
- 门诊手术中心
- 家庭医疗保健
- 其他的
根据最终用户，莱伯先天性黑蒙市场分为医院、专科诊所、门诊手术中心、家庭医疗保健和其他。
分销渠道
- 零售销售
- 直接招标
根据分销渠道，莱伯先天性黑蒙市场细分为零售、直接招标。
莱伯先天性黑蒙症市场 区域分析/见解
对莱伯先天性黑蒙市场进行了分析，并按国家、疾病类型、类型、最终用户和分销渠道提供了市场规模洞察和趋势。
莱伯先天性黑蒙市场报告涵盖的国家包括美国、加拿大和墨西哥。
由于不断增加的管道产品和临床试验，美国预计将占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和份额分析
北美莱伯先天性黑蒙市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对莱伯先天性黑蒙市场的关注有关。
一些主要参与者包括 Invitae Corporation、强生服务公司、Spark Therapeutics 公司、LKC TECHNOLOGIES 公司、Amarantus Bioscience Holdings 公司、Sucampo Pharmaceuticals 公司、Orphagen Pharmaceuticals 公司等。
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、北美与地区以及供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PIPELINE ANALYSIS FOR NORTH AMERICA LEBER CONGENTIAL AMAUROSIS MARKET
4.2 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS
4.3 PESTEL ANALYSIS
4.4 PORTERS FIVE FORCES
5 EPIDEMIOLOGY
6 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
6.2 RESTRAINTS
6.2.1 LACK OF QUALIFIED PROFESSIONALS
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE
6.3 OPPORTUNITIES
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS
7 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 INFANTILE TYPE
7.3 JUVENILE TYPE
7.4 OTHERS
8 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE
8.1 OVERVIEW
8.2 THERAPY
8.2.1 GENE THERAPY
8.2.1.1 LUXTURNA
8.2.2 RETINAL PROSTHETIC
8.2.3 NEUROPROTECTIVE AGENTS
8.2.3.1 VITAMIN A PALMITATE
8.2.3.2 DOCOSAHEXAENOIC ACID
8.2.3.3 LUTEIN
8.2.3.4 OTHERS
8.2.4 OTHERS
8.3 DIAGNOSIS
8.3.1 CLINICAL DIAGNOSIS
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
8.3.1.1.2 DARK ADAPTOMETRY (DA)
8.3.1.2 RETINAL IMAGING
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING
8.3.1.3 VISUAL FIELD TEST
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
8.3.1.3.2 MANUAL FIELD TEST
8.3.1.4 CLINICAL EYE EXAMINATION
8.3.1.4.1 SLIT LAMP
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY
8.3.1.4.3 REFRACTION TEST
8.3.1.4.4 DILATION EXAM
8.3.1.5 OTHERS
8.3.2 GENETIC DIAGNOSIS
9 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALITY CLINICS
9.4 AMBULATORY SURGICAL CENTERS
9.5 HOME HEALTHCARE
9.6 OTHERS
10 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 RETAIL SALES
10.2.1.1 HOSPITAL PHARMACIES
10.2.1.2 RETAIL PHARMACIES
10.2.1.3 OTHERS
10.3 DIRECT TENDER
11 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 SPARK THERAPEUTICS, INC
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.1.4.1 EU AUTHORIZATION
14.2 OPTOS
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.2.4.1 PRODUCT APPROVAL
14.3 CD GENOMICS
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.4.5.1 COLLABORATION
14.5 LKC TECHNOLOGIES, INC
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.5.4.1 PRODUCT APPROVAL
14.5.5 PRODUCT APPROVAL
14.6 AGTC
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.6.4.1 AGREEMENT
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ASTELLAS PHARMA INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ATSENA THERAPEUTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 CENTOGENE N.V.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.10.4.1 PRODUCT LAUNCH
14.11 COAVE THERAPEUTICS
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 EDITAS MEDICINE
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.12.4.1 DATA & TRAIL DATA PRESENTATION
14.13 ELUMINEX BIOSCIENCES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 GYROSCOPE THERAPEUTICS LIMITED
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 INVITAE CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.15.4.1 NEW FACILITY
14.15.4.2 EXPANSION
14.16 IVERIC BIO.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 MEIRAGTX LIMITED
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 METROVISION
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.19.3.1 FDA CLEARANCE APPROVAL
14.2 OCUGEN INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 OKUVISION
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
14.21.3.1 APPROVAL
14.22 PROQR THERAPEUTICS
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 REGENXBIO INC.
14.23.1 COMPANY SNAPSHOT
14.23.2 REVENUE ANALYSIS
14.23.3 PRODUCT PORTFOLIO
14.23.4 RECENT DEVELOPMENTS
14.24 SPARINGVISION
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 28 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 43 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 U.S. THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 U.S. GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 U.S. NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 U.S. DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 U.S. CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 U.S. RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 U.S. VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 U.S. CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 U.S. RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 57 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 CANADA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 CANADA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CANADA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 CANADA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 CANADA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 CANADA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CANADA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 CANADA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 CANADA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 CANADA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 70 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 71 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 MEXICO THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 MEXICO GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 MEXICO NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 MEXICO DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 MEXICO CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 MEXICO RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 MEXICO ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 MEXICO VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 MEXICO CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 82 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 83 MEXICO RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: END USER GRID
FIGURE 9 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 11 RISING GOVERNMENT AWARENESS PROGRAMS ABOUT THE INHERITED RETINAL DISEASE IS EXPECTED TO DRIVE THE NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INFANTILE TYPE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET
FIGURE 15 PROPORTION OF RPE65 GENE MUTATION IN CLINICALLY DIAGNOSED LCA PATIENTS
FIGURE 16 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2021
FIGURE 17 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 18 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2021
FIGURE 21 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2021
FIGURE 25 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 29 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 30 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 33 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 34 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 35 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 36 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 37 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
